Drug Targets

C. Ola Landgren and colleagues discuss adapting to a field transformed by new immunotherapy drugs and targeted therapies and how to best combine treatments

The open comment period begins August 22 and will close on September 12, 2024

Phase 2 trial results indicate benefits of the new way of treating advanced ER+ breast cancer

Second generation of the Cancer Dependency Map uncovers priority drug targets with strong links to specific cancer types

Water purity can drastically impact quality control during drug discovery, validation, and characterization  

The hit-to-lead and lead optimization stages of novel therapeutic characterization require sensitive, water-dependent experiments 

Findings point to the potential for using existing cancer therapies to treat drug-resistant epilepsy

Carolyn R. Bertozzi, PhD, is credited for inventing biorthogonal chemistry and “copper-free click chemistry”

Study identifies blood proteins that indicate which patients with iMCD are most likely to benefit from siltuximab